Advances in Ophthalmology & Visual System

ONIT Pub Cover

Ocular Nutrition Impact on Tear Film Study (ONIT)

Volume 2 Issue 2 – 2015 Sean P Mulqueeny, Robert L Davis, William D Townsend, and Bruce H Koffler Mulqueeny Eye Centers, USA *Corresponding author: Sean P Mulqueeny, Mulqueeny Eye Centers, 612 N New Ballas Road, Saint Louis, MO 63141, Tel: 314-542-3600; Email: Received: January 27, 2015 | Published: March 26, 2015

Abstract

Purpose: To better understand the role of a proprietary dietary supplement formulated to contain Omega 3 and seven other anti-inflammatories plays in patients with established clinical findings consistent with occasional dry eye disease. Secondarily, this evaluation will attempt to discover if any of the diagnostic markers are predictive to the therapeutic approach of omega 3 anti- inflammatory dietary supplements.

Design: Clinic-based, multi-center cohort study.

Methods: This eight-week feasibility study was to determine if subjects presenting with occasional dry eye confirmed by diagnostic markers and symptoms responded to nutritional therapy via an oral nutritional supplement (EyePromise EZ Tears). Analyses were completed on a subgroup of subjects with 4 of 7 possible diagnostic criteria.

Results: A total of 67 patients were enrolled between 18-79 years of age inclusive. At the conclusion of the study, improvement from baseline was demonstrated in OSDI decreasing scores by 38%. Improved tear breakup time and phenol red thread scores were seen and was reduced conjunctival staining. There was also a decrease noted in lid inflammation. Osmolarity scores were variable and inconclusive.

Conclusion: Supplementation with this Omega-3 anti-inflammatory product in occasional dry eye showed significant improvement in OSDI, TBUT, conjunctival staining, lid inflammation, and phenol red thread, tear meniscus, and corneal staining scores. This decrease in patient symptoms could be an indication of decreasing ocular surface inflammation and possible stabilization of the lipid layer. The change from baseline for these signs appears to be rapid, as differences were shown as early as one-week post-supplementation.

ONIT Clinical Research Study – AOVS-02-00038